y's history," said Mr. Moch. "I believe that BME's unique technology and innovative products have tremendous commercial growth potential. Together with BME's talented employees, I look forward to accelerating the growth of the Company and broadening the use of our novel memory metal implants."
"Ken's involvement is a statement to our distributor partners that we intend to grow our business for our mutual benefit. With in-house manufacturing now on line at BME we have the capability, support and focus for new product development and the continued improvement of our product lines," said Casey Fox, PhD.
About BioMedical Enterprises, Inc.
BME designs, manufactures and markets memory metal implants used in orthopaedic reconstructive surgery and fracture management. BME's patented implant system utilizes the unique properties of the shape memory alloy nitinol to provide controlled long-term compression that enhances the body's natural healing process in an effort to achieve faster healing times and fewer complications. BME's barbed and smooth OSStaple(TM) lines of bone fusion implants, part of the OSSforce(TM) fixation system, are designed to achieve controlled long-term compression of bone fragments. BME's OSSAnchor(TM) line of soft tissue fixation implants give surgeons a simple yet powerful tool to attach soft tissue to bone.
For more information about BME and its unique products visit http://www.bme-tx.com.
'/>"/>SOURCE BioMedical Enterprises, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine news :1.
5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes2.
Response Biomedical Corporation Announces Change of Executives3.
AutismActionPlan.org Launches Doctor-Driven Biomedical Autism Treatment Website4.
ASH Holds a Special Symposium to Interest High School Students in Biomedical Research5.
ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research6.
Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial7.
Environmental Tectonics Corporations BioMedical Systems Division Announces Additional Sales of its Baramed Monoplace Chambers8.
Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% : Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases 9.
Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference10.
Interview with Dr. Elisabeth Hager, CEO of Balan Biomedical, Inc., to Air Nationally on Sky Radio11.
Response Biomedical Closes $5.1 Million Financing